Therapeutic Goods Administration provisionally approves the usage of the Pfizer–BioNTech COVID-19 vaccine for children between the ages of 5 and 11 years.
The Therapeutic Goods Administration provisionally approves the usage of the Pfizer–BioNTech COVID-19 vaccine for children between the ages of 5 and 11 years. Vaccination rollout for this age group will begin on January 10, once ATAGI gives its recommendation.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan to read this report and the complete Premium retrospective archive.
HealthTherapeutic Goods Administration provisionally approves the usage of the Pfizer–BioNTech COVID-19 vaccine for children between the ages of 5 and 11 years.
View Premium plansBrowse free archive reportsThe Therapeutic Goods Administration provisionally approves the usage of the Pfizer–BioNTech COVID-19 vaccine for children between the ages of 5 and 11 years. Vaccination rollout for this age group will begin on January 10, once ATAGI gives its recommendation.